Delivery Order SPE2DB22D2206-SPE2DB25FHL33
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zoladex 10.8 mg implant syringes under a firm fixed-price contract with a ceiling value of $7,564.32. The contract is scheduled for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $5,578.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zoladex 10.8 mg implant syringes, with completion scheduled for October 14, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $1,985.82 delivery order to AmerisourceBergen Drug Corp for the supply of Zoladex 3.6 mg implant syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by September 3, 2025, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and represents a single transaction within AmerisourceBergen's broader federal pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,297.50 on August 12, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a completion date of September 3, 2025. This non-set-aside, competitively awarded contract carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $16,735.50 for Zoladex 10.8 mg implant syringes on August 8, 2025, with completion targeted for August 29, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $11,757.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zoladex 10.8 mg implant syringes, with an ultimate completion date of November 10, 2025. This non-set-aside contract was competitively awarded on October 20, 2025, with performance to be conducted at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $3,719.00 and ultimate completion date of October 1, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $3,971.64 to AmerisourceBergen Drug Corp for the supply of Zoladex 3.6 mg implant syringes. This firm fixed-price delivery order, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a contract ceiling value of $37,190. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive award. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zoladex 3.6 mg implant syringes, with a ceiling value of $3,971.64 and an ultimate completion date of October 14, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHL33Delivery Order
The Defense Logistics Agency awarded a $1,985.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of Zoladex 3.6 mg implant syringes, with an ultimate completion date of July 8, 2025. This is a non-set-aside contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The delivery order represents a small-value transaction within AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Zoladex, a hormone treatment used primarily in oncology and endocrinology applications, demonstrates the company's capability to fulfill specialized pharmaceutical needs across multiple therapeutic domains. AmerisourceBergen's federal contract portfolio reflects consistent competitively awarded delivery orders with firm fixed pricing, underscoring its versatility in meeting federal medical supply requirements for the military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 6/13/25 |